BioRestorative Therapies, Inc.

BRTX

US0906556065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
1.68 ^USD	-4.00%		-6.15%	-3.44%

27/06	BioRestorative Therapies, Inc. Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program	CI
13/06	Top Midday Gainers	MT

BioRestorative Therapies, Inc. announced that it has received $0.675 million in funding

January 07, 2019

On January 7, 2019, BioRestorative Therapies, Inc. (OTCPK:BRTX) closed the transaction.

Latest news about BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program	27/06	CI
Top Midday Gainers	13/06	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	13/06	MT
Sector Update: Health Care	13/06	MT
BioRestorative Therapies in Licensing Talks for Metabolic Disease Program -- Shares Rise Pre-Bell	13/06	MT
Exchange-Traded Funds Edge Higher, Equity Futures Mixed Pre-Bell Thursday Ahead of Key Economic Data	13/06	MT
BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	12/06	CI
BioRestorative Announces Signing a Five-Year Exclusive Supply Agreement with Cartessa Aesthetics, LLC	15/05	CI
BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity	08/05	CI
BioRestorative Therapies, Inc. Announces Transformative Commercial Agreement with Cartessa Aesthetics, LLC	30/04	CI
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment	16/04	DJ
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial	16/04	MT
BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment	16/04	CI
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease	08/04	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting	14/02	CI
Top Midday Decliners	07/02	MT
Top Premarket Decliners	06/02	MT
BioRestorative Therapies Reports Positive Results From Lumbar Disc Treatment Candidate Trial; Shares Rise	05/02	MT
BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease	05/02	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Sector Update: Health Care Stocks Lower Late Afternoon	19/23/19	MT
Sector Update: Health Care Stocks Mixed Monday Afternoon	18/23/18	MT
Sector Update: Health Care	18/23/18	MT
BioRestorative Therapies Shares Rise After Shareholder Broadrick Dale Boosts Stake	18/23/18	MT

Chart BioRestorative Therapies, Inc.

Duration

Period

More charts

BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Ratings for BioRestorative Therapies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.68 USD

Average target price

10.5 USD

Spread / Average Target

+525.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIORESTORATIVE THERAPIES, INC.	-3.44%	11.37M
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+22.91%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-14.01%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B
INSMED INCORPORATED	+143.76%	12.18B

Bio Therapeutic Drugs